PMID- 26472417 OWN - NLM STAT- MEDLINE DCOM- 20160819 LR - 20191210 IS - 1499-2752 (Electronic) IS - 0315-162X (Linking) VI - 42 IP - 11 DP - 2015 Nov TI - Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis. PG - 2066-70 LID - 10.3899/jrheum.150478 [doi] AB - OBJECTIVE: Remission is the primary aim in the treatment of patients with rheumatoid arthritis (RA). In this study, we aimed to evaluate biomarker profiles of patients in remission by different criteria and compare these profiles with controls. METHODS: Serum levels of calprotectin, interleukin 6 (IL-6), type II collagen helical peptide, C-terminal crosslinking telopeptide of type I collagen generated by matrix metalloproteinases (ICTP), matrix metalloproteinase 3 (MMP-3), resistin, and leptin were measured by ELISA in 80 patients. The patients were in Disease Activity Score at 28 joints with erythrocyte sedimentation rate (DAS28-ESR) remission, and had these characteristics: female/male 54/26, mean age 51.4 +/- 12.1 years, mean disease duration 11.4 +/- 8.1 years, rheumatoid factor positivity 68.7% (n = 55), anticyclic citrullinated peptide positivity 60.7% (n = 48). These patients were also evaluated for the American College of Rheumatology/European League Against Rheumatism (Boolean) and Simple Disease Activity Index (SDAI) remissions. Additionally, 80 age-, sex-, and comorbidity-matched individuals without rheumatic diseases were included in the study as controls. RESULTS: At recruitment of 80 patients in DAS28 remission, 33 patients (41.2%) were found in Boolean remission and 39 patients (48.7%) were in SDAI remission. Serum MMP-3, ICTP, resistin, and IL-6 levels of the 80 patients in DAS28 remission were statistically significantly higher than the controls. Patients in Boolean and SDAI remissions had significantly higher serum ICTP, resistin, and IL-6 levels in comparison with the controls. CONCLUSION: The 3 commonly used remission criteria of RA are almost similar with regard to patients' biomarker levels. Biomarker profiles of patients may provide complementary information to clinical evaluation of remission and may help to determine the patients under the risk of progression. FAU - Yilmaz-Oner, Sibel AU - Yilmaz-Oner S AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. FAU - Ozen, Gulsen AU - Ozen G AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. FAU - Can, Meryem AU - Can M AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. FAU - Atagunduz, Pamir AU - Atagunduz P AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. FAU - Direskeneli, Haner AU - Direskeneli H AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. FAU - Inanc, Nevsun AU - Inanc N AD - From the Department of Rheumatology, Medical Faculty, Marmara University, Istanbul, Turkey.S. Yilmaz-Oner, MD, Marmara University, Medical Faculty, Department of Rheumatology; G. Ozen, MD, Marmara University, Medical Faculty, Department of Rheumatology; M. Can, MD, Marmara University, Medical Faculty, Department of Rheumatology; P. Atagunduz, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; H. Direskeneli, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology; N. Inanc, MD, Professor, Marmara University, Medical Faculty, Department of Rheumatology. inanc.nevsun@gmail.com. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20151015 PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Antirheumatic Agents) RN - 0 (Biomarkers) RN - 0 (Interleukin-6) RN - 0 (Leptin) RN - 0 (Leukocyte L1 Antigen Complex) RN - 9007-41-4 (C-Reactive Protein) RN - 9009-79-4 (Rheumatoid Factor) RN - EC 3.4.24.17 (MMP3 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Adult MH - Age Factors MH - Analysis of Variance MH - Antirheumatic Agents/*therapeutic use MH - Arthritis, Rheumatoid/*blood/*drug therapy/physiopathology MH - Biomarkers/*blood MH - Blood Sedimentation MH - C-Reactive Protein/metabolism MH - Case-Control Studies MH - Disease Progression MH - Female MH - Humans MH - Interleukin-6/blood MH - Leptin/blood MH - Leukocyte L1 Antigen Complex/blood MH - Male MH - Matrix Metalloproteinase 3/blood/metabolism MH - Middle Aged MH - Prognosis MH - Remission Induction MH - Retrospective Studies MH - Rheumatoid Factor/blood MH - Risk Assessment MH - Severity of Illness Index MH - Sex Factors MH - Statistics, Nonparametric MH - Treatment Outcome OTO - NOTNLM OT - BIOMARKERS OT - REMISSION CRITERIA OT - RHEUMATOID ARTHRITIS EDAT- 2015/10/17 06:00 MHDA- 2016/08/20 06:00 CRDT- 2015/10/17 06:00 PHST- 2015/07/28 00:00 [accepted] PHST- 2015/10/17 06:00 [entrez] PHST- 2015/10/17 06:00 [pubmed] PHST- 2016/08/20 06:00 [medline] AID - jrheum.150478 [pii] AID - 10.3899/jrheum.150478 [doi] PST - ppublish SO - J Rheumatol. 2015 Nov;42(11):2066-70. doi: 10.3899/jrheum.150478. Epub 2015 Oct 15.